Jorge Arana1, Adamma Mba-Jonas2, Christopher Jankosky2, Paige Lewis3, Pedro L Moro3, Tom T Shimabukuro3, Maria Cano3. 1. Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: JArana@cdc.gov. 2. Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. 3. Immunization Safety Office, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
PURPOSE: Human papillomavirus (HPV) vaccination prevents infections with HPV strains that cause certain cancers. Reports of postural orthostatic tachycardia syndrome (POTS) following HPV vaccination have raised safety concerns. We reviewed POTS reports submitted to the Vaccine Adverse Event Reporting System (VAERS). METHODS: We searched the VAERS database for reports of POTS following any type of HPV vaccination (bivalent, quadrivalent, or nonavalent) from June 2006 to August 2015. We reviewed reports and applied established POTS diagnostic criteria. We calculated unadjusted POTS case reporting rates based on HPV vaccine doses distributed and conducted empirical Bayesian data mining to screen for disproportional reporting of POTS following HPV vaccination. RESULTS: Among 40,735 VAERS reports following HPV vaccination, we identified 29 POTS reports that fully met diagnostic criteria. Of these, 27 (93.1%) were in females and mean age was 14 years (range 12-32). Median time from vaccination to start of symptoms was 43 days (range 0-407); most (18, 75.0%) had onset between 0 and 90 days. Symptoms frequently reported concomitantly included headache (22, 75.9%) and dizziness (21, 72.4%). Twenty (68.9%) reports documented a history of pre-existing medical conditions, of which chronic fatigue (5, 17.2%), asthma (4, 13.8%), and chronic headache (3, 10.3%) were most common. Approximately one POTS case is reported for every 6.5 million HPV vaccine doses distributed in the United States. No empirical Bayesian data mining safety signals for POTS and HPV vaccination were detected. CONCLUSIONS: POTS is rarely reported following HPV vaccination. Our review did not detect any unusual or unexpected reporting patterns that would suggest a safety problem. Published by Elsevier Inc.
PURPOSE:Human papillomavirus (HPV) vaccination prevents infections with HPV strains that cause certain cancers. Reports of postural orthostatic tachycardia syndrome (POTS) following HPV vaccination have raised safety concerns. We reviewed POTS reports submitted to the Vaccine Adverse Event Reporting System (VAERS). METHODS: We searched the VAERS database for reports of POTS following any type of HPV vaccination (bivalent, quadrivalent, or nonavalent) from June 2006 to August 2015. We reviewed reports and applied established POTS diagnostic criteria. We calculated unadjusted POTS case reporting rates based on HPV vaccine doses distributed and conducted empirical Bayesian data mining to screen for disproportional reporting of POTS following HPV vaccination. RESULTS: Among 40,735 VAERS reports following HPV vaccination, we identified 29 POTS reports that fully met diagnostic criteria. Of these, 27 (93.1%) were in females and mean age was 14 years (range 12-32). Median time from vaccination to start of symptoms was 43 days (range 0-407); most (18, 75.0%) had onset between 0 and 90 days. Symptoms frequently reported concomitantly included headache (22, 75.9%) and dizziness (21, 72.4%). Twenty (68.9%) reports documented a history of pre-existing medical conditions, of which chronic fatigue (5, 17.2%), asthma (4, 13.8%), and chronic headache (3, 10.3%) were most common. Approximately one POTS case is reported for every 6.5 million HPV vaccine doses distributed in the United States. No empirical Bayesian data mining safety signals for POTS and HPV vaccination were detected. CONCLUSIONS: POTS is rarely reported following HPV vaccination. Our review did not detect any unusual or unexpected reporting patterns that would suggest a safety problem. Published by Elsevier Inc.
Entities:
Keywords:
Human papillomavirus (HPV); Human papillomavirus (HPV) vaccine; Postural orthostatic tachycardia syndrome (POTS); Vaccine Adverse Event Reporting System (VAERS); Vaccine adverse event; Vaccine safety
Authors: Tom T Shimabukuro; John R Su; Paige L Marquez; Adamma Mba-Jonas; Jorge E Arana; Maria V Cano Journal: Pediatrics Date: 2019-11-18 Impact factor: 7.124
Authors: Alexandru Barboi; Christopher H Gibbons; Felicia Axelrod; Eduardo E Benarroch; Italo Biaggioni; Mark W Chapleau; Gisela Chelimsky; Thomas Chelimsky; William P Cheshire; Victoria E Claydon; Roy Freeman; David S Goldstein; Michael J Joyner; Horacio Kaufmann; Phillip A Low; Lucy Norcliffe-Kaufmann; David Robertson; Cyndya A Shibao; Wolfgang Singer; Howard Snapper; Steven Vernino; Satish R Raj Journal: Clin Auton Res Date: 2019-09-02 Impact factor: 4.435
Authors: Daniel A Salmon; Paul Henri Lambert; Hanna M Nohynek; Julianne Gee; Umesh D Parashar; Jacqueline E Tate; Annelies Wilder-Smith; Kenneth Y Hartigan-Go; Peter G Smith; Patrick Louis F Zuber Journal: BMJ Glob Health Date: 2021-05
Authors: Anders Hviid; Nicklas M Thorsen; Louise N Thomsen; Frederik T Møller; Andreas Wiwe; Morten Frisch; Palle Valentiner-Branth; Dorte Rytter; Kåre Mølbak Journal: Int J Epidemiol Date: 2021-05-17 Impact factor: 7.196
Authors: Brian Olshansky; David Cannom; Artur Fedorowski; Julian Stewart; Christopher Gibbons; Richard Sutton; Win-Kuang Shen; James Muldowney; Tae Hwan Chung; Suzy Feigofsky; Hemal Nayak; Hugh Calkins; David G Benditt Journal: Prog Cardiovasc Dis Date: 2020-03-25 Impact factor: 11.278